ArticleAnnals of surgical oncology2025
Left Hepatectomy Enlarged to Segment 1 with Total Vascular Exclusion of the Liver Preserving the Caval Flow with Temporary Portacaval Shunt and Hypothermic Oxygenated Portal Perfusion on Machine for Metastatic Recurrence of a Pleural Chondrosarcoma.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Two-Stage Hepatectomy for Cholangiocarcinoma Under Total Vascular Exclusion with Veno-venous ECMO Bypass and Controlled Closed-loop In Situ Hypothermic Oxygenated Perfusion of the Liver: The Hannover CLIP-Concept.Annals of surgical oncology · 2026Article
- Hypothermic Oxygenated Machine Perfusion (HOPE) During Total Vascular Exclusion With Veno-Venous Bypass for Giant Hepatic Hemangioma Resection.Artificial organs · 2025Article
- Hypothermic oxygenated machine perfusion forHepatobiliary surgery and nutrition · 2025Article
- ASO Author Reflections: Could the Use of a Hypothermic Oxygenated Machine Perfusion Improve Postoperative Outcome After In Situ Hypothermic, Ante Situm, and Ex Situ Liver Resection?Annals of surgical oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTotal vascular exclusion (TVE) of the liver preserving the caval flow with portal hypothermic perfusion and temporary portacaval shunt (PCS) is a validated technique for tumors invading the hepatic veins (HV) close to their confluence with the inferior vena cava (IVC). It prevents the risk of haemorrhage, gas embolism and avoids the haemodynamic consequences of clamping the IVC and veno-venous bypass. No published cases have reported using hypothermic oxygenated perfusion machine. PATIENTS AND
methodsThe patient was a 58-year-old woman presenting a recurrent metastatic pleural chondrosarcoma, with a pleural metastasis and several intra-abdominal metastases, including a lesion localized in segment 1 close to the hilar plate and invading the left HV near its abutment in the IVC. A left hepatectomy enlarged to segment 1 was performed under TVE preserving the caval flow with in situ hypothermic portal perfusion of the liver using perfusion machine.
resultsPV clamping lasted 57 min, and 2 l of preservative solution were perfused. The maximum pressure in the PV was 10 mmHg and oxygen flow was regulated at 2 L/min. The resection was complete and margins were negative. Liver temperature was monitored at 5-6 °C. Postoperative follow-up was favourable, with hospital discharge at 16 days after surgery. DISCUSSION: The use of hypothermic oxygenated perfusion machine is therefore possible in this technique. In parallel with the results obtained in liver transplantation on marginal grafts, it could probably reduce ischemia-reperfusion injury of the remnant parenchyma compared with static cold storage and improve post-operative outcome.
Indexed as
Identifiers
40106110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.